Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Pediatr Gastroenterol Nutr ; 72(4): 506-510, 2021 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-33230080

RESUMEN

OBJECTIVES: The aim of the study was to assess the efficacy, safety and side-effect profile of ferric carboxymaltose (FCM) for correcting IDA in children and adolescents in paediatric gastroenterology, hepatology, and nutrition. METHOD: This was a retrospective study of all gastroenterology patients <18 years who had FCM (October 2015 to October 2017). Haematological and biochemical parameters were recorded pre-infusion, at 4 weeks, 3 months, 6 months, and 1 year post-infusion. Recognised side-effects were documented. RESULTS: Sixty-six children received FCM during this period. Data was analysed on 61 children, 5 excluded because of inadequate data. The median age at administration was 14 years (IQR 7). Thirty-two (52%) were boys. Twenty-six (42%) were <14 years old. Seven (11.5%) were <5 years old. Seventeen (28%) were switched from oral iron supplements to FCM. The median dose of FCM delivered was 19 mg/kg. The median haemoglobin increased from 108 to 126 g/L at 1 month post-infusion (P value <0.00001). The mean cell volume also improved from 80 to 84 fL at 1 month post-infusion (P value = 0.0007). Forty-eight (94%) children corrected their anaemia after receiving FCM. Two patients (3%) reported side-effects with skin bruising and staining. CONCLUSIONS: FCM appears to be effective in correcting IDA in children across a wide range of gastroenterology indications and all ages. It is effective and generally well tolerated including in very young patients. Potential side-effects can be avoided by careful monitoring during infusions.


Asunto(s)
Anemia Ferropénica , Gastroenterología , Adolescente , Anemia Ferropénica/tratamiento farmacológico , Niño , Preescolar , Compuestos Férricos/efectos adversos , Humanos , Infusiones Intravenosas , Masculino , Maltosa/análogos & derivados , Estudios Retrospectivos
2.
J Assoc Physicians India ; 55: 861-5, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18405135

RESUMEN

A 56 years male diabetic patient presented with recurrent left upper lobe pneumonia. Fiberoptic bronchoscopy revealed extraluminal compression of left main bronchus with an endobronchial mass obstructing the left upper lobe orifice. The lesion resembled bronchial adenoma. However histological examination revealed mucormycosis. Timely diagnosis followed by medical intervention with intravenous Amphotericin B, coupled with proper management of diabetes, ablated the tumor. Relevant literature on the subject is reviewed.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Mucormicosis/tratamiento farmacológico , Anfotericina B/administración & dosificación , Antifúngicos/administración & dosificación , Broncoscopía , Diabetes Mellitus , Humanos , Inyecciones Intravenosas , Enfermedades Pulmonares Fúngicas/diagnóstico , Masculino , Persona de Mediana Edad , Mucormicosis/diagnóstico , Neumonía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...